Levofloxacin (Levaquin)

01/01/2017 - "PTAs were optimal (>80%) against Escherichia coli and Haemophilus influenzae, borderline against Staphylococcus aureus, and suboptimal against Pseudomonas aeruginosa The levofloxacin doses defined in our study may be effective for the treatment of infections due to bacterial pathogens, with an MIC of ≤0.5 mg/liter in older patients with various degrees of renal function, while minimizing the toxicity risk. "
08/15/2002 - "This study tested whether levofloxacin, at a new high dose of 750 mg, was effective for the treatment of complicated skin and skin-structure infections (SSSIs). "
01/01/2004 - "High-dose levofloxacin is able to exploit these pharmacokinetic features to provide an effective treatment for severe infections. "
08/01/2003 - "The levofloxacin clinical results extrapolated from published studies document the efficacy of levofloxacin in the treatment of infections sustained by P. "
01/01/2003 - "pneumoniae resistance to levofloxacin is <1% overall in the US.A number of randomised comparative trials in the US have demonstrated the efficacy of levofloxacin in the treatment of infections of the respiratory tract, genitourinary tract, skin and skin structures. "

11/01/2003 - "Levofloxacin has improved anti-gram-positive potency, PK/PD properties, a proven clinical trial record (particularly for communityacquired pneumonia [CAP]), and an excellent safety profile-in the context of the treatment of >250 million patients worldwide in the past decade. "
09/01/2002 - "We conclude that levofloxacin is effective against experimental pneumonia due to pneumococci with MIC < 1.5 mg/L, ineffective on experimental pneumonia due to pneumococci with MIC > or = 2 mg/L, and could be associated with the appearance of mutants when a parC mutation is pre-existing."
07/01/1998 - "In experimental pneumonia in guinea pigs, in which the biofilm mode of growth of the strain was observed in the lung, only levofloxacin exhibited substantial therapeutic efficacy. "
06/01/2004 - "Data from six clinical trials encompassing 1,997 total patients have been analyzed to determine the efficacy of levofloxacin (500 mg qd or 750 mg qd) in treating patients with community-acquired pneumonia (CAP) due to Legionella. "
06/15/2002 - "THE EFFICACY OF LEVOFLOXACIN: In treating community-acquired pneumonia (CAP) has been assessed during 5 large clinical trials (including 4 controlled randomized trials). "

03/01/2003 - "These study results indicate that levofloxacin 250 mg orally once daily for 10 days is an effective and well tolerated treatment of complicated urinary tract infections."
01/01/2019 - "He had been treated for a urinary tract infection twice over the past 3 weeks with prolonged courses of levofloxacin; while his urinary symptoms improved, his respiratory symptoms did not. "
11/01/2001 - "[Efficacy of a single-day administration of levofloxacin for the prevention of urinary tract infections after urogenital examinations and treatments for outpatients]."
05/21/2023 - "There is no significant difference between a single dose of 500 mg of Levofloxacin administered one hour before the urodynamic study and a once-daily dose of 500 mg of Levofloxacin for three days following the urodynamic study related to urinary tract infections prevention post-urodynamic examination."
05/21/2023 - "The current study aims to compare the effectiveness of pre-urodynamic single-dose levofloxacin and post-urodynamic levofloxacin for three days related to the incidence of urinary tract infections post-urodynamic examination. "

04/01/2007 - "[Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis]."
04/01/2007 - "To study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis. "
06/01/2010 - "To compare the safety and efficacy of levofloxacin 750 mg QD for 2 weeks or levofloxacin 750 mg QD for 3 weeks to levofloxacin 500 mg QD for 4 weeks in treating chronic bacterial prostatitis (CBP). "
06/01/2010 - "Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis."
01/01/2019 - "Levofloxacin for NIH Category II Chronic Bacterial Prostatitis: A Real-Life Study."

07/20/2005 - "500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. "
06/01/1999 - "These in-vitro results suggest that levofloxacin may be useful in the treatment of community-acquired lower respiratory tract infections."
01/01/2019 - "Efficacy of levofloxacin against biofilms of Pseudomonas aeruginosa isolated from patients with respiratory tract infections in vitro."
02/01/2011 - "A broad range of Gram-positive and Gram-negative of levofloxacin was confirmed in clinical trials in patients with respiratory tract infections. "
08/01/2010 - "The purpose of the study was to assess the bactericidal effects of a single oral dose of levofloxacin (LVFX) by examining the concentration of LVFX in alveolar epithelial lining fluid (ELF) from patients with lower respiratory tract infections (LRTI). "